ClinicalTrials.gg
CompletedNCT02896868Updated May 3, 2019

A Study of LY3041658 in Participants With Skin Diseases

A Phase 1 interventional study of LY3041658 and Placebo in Skin Diseases and Psoriasis, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-03.

Primary conditionPsoriasisRegistry: Skin DiseasesReclassifiedWhy we changed it
Registry
Skin Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Psoriasis
Why
  1. The study's listed conditions name Psoriasis, a narrower term within Skin Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Planned enrollment
25th of 36
60 · median 181
Started
2016
with 4 others
Phase 1
9 of 36
none open now
Registered
16th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 25th largest by planned enrollment, is one of 5 that started in 2016, is one of 9 in phase 1, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.

03

Conditions studied

  • Skin Diseases
  • Psoriasis

Browse trials for

04

In context

Psoriasis Reclassified

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Psoriasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator confirmed diagnosis of certain skin diseases for at least 6 months.
  • Active skin lesions that are not responding to standard therapies.
  • Willing to undergo pre- and post-treatment skin of lesions.

Exclusion criteria

Exclusion Criteria:

  • Have other skin diseases that may interfere with evaluation of the specified skin disease being studied.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    LY3041658

    LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).

    Drug: LY3041658

  • Placebo comparator
    Placebo

    Placebo administered IV once every two weeks over 6 weeks (four doses).

    Drug: Placebo

Interventions

  • Administered IV.

  • DrugPlacebo

    Administered IV.

07

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    Time frame: Dosing Day 1 through Day 127

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658

    Time frame: Dosing Day 1 through Day 127

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) During Dosing Interval at Steady State (AUCss) of LY3041658

    Time frame: Dosing Day 1 through Day 127

  3. Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY3041658

    Time frame: Dosing Day 1 through Day 127

08

Study locations

5 sites
  • Parexel Early Phase Unit at Glendale
    Glendale, California 91206-4140, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46256, United States
  • PAREXEL-Phase 1 Baltimore Harbor Hospital Center
    Baltimore, Maryland 21225, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2019, 28 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 28 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2016
First posted
Sep 12, 2016
StartActual
Nov 8, 2016
Primary completionActual
Mar 19, 2019
CompletionActual
Mar 19, 2019
Last update
May 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02896868
Responsible party
Sponsor
First posted
Sep 12, 2016
Start date
Nov 8, 2016
Primary completion
Mar 19, 2019
Completion
Mar 19, 2019
Last update
May 3, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrekibart

Start the discussion